Phase 2 Clinical Trial Results for a First Generation Stem Cell Therapy to Treat Frailty

First generation stem cell therapies are simple in concept, a matter of transplanting cells taken from person A into person B in the hope of producing benefits, but the implementation hides a great deal of complexity. Tissue is provided by donors, cells are selected from that tissue, the resulting population of cells is expanded in culture, their behavior and state may be modified in simple ways via the addition of factors, the cells are manufactured into doses that can be frozen, and then injected into patients. For every one of those steps there are many, many different approaches, refinements, and epicycles. It remains poorly understood as to why the outcomes of this class of therapy are so variable, even for clinics practicing what seem to be similar methodologies. It is hard to say why the (allegedly) more successful implementations are in fact more successful, particularly since most of them are owned by individual clinics and will never be the subject of formal clinical trials. Near all such stem cell transplants reliably reduce chronic inflammation. This, at least, is fairly consistent across approaches. This outcome occurs due to signaling by the transplanted cells, and can last for months. The cells themselves near all die much more rapidly than that, though it is the case that a few clinics and approaches claim a meaningful degree of cell engraftment and survival. Beyond reductions in chronic inflammation, lasting improvement in tissue function or a r...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs